Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $22.0 million.

  • GeneDx Holdings' Depreciation & Amortization (CF) rose 9.19% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 6.28%. This contributed to the annual value of $22.0 million for FY2024, which is 34.92% down from last year.
  • Latest data reveals that GeneDx Holdings reported Depreciation & Amortization (CF) of $22.0 million as of FY2024, which was down 34.92% from $33.7 million recorded in FY2023.
  • GeneDx Holdings' 5-year Depreciation & Amortization (CF) high stood at $59.3 million for FY2022, and its period low was $11.7 million during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $38.3 million, with a median of $33.7 million in 2023.
  • As far as peak fluctuations go, GeneDx Holdings' Depreciation & Amortization (CF) surged by 171.97% in 2022, and later plummeted by 43.12% in 2023.
  • Over the past 5 years, GeneDx Holdings' Depreciation & Amortization (CF) (Yearly) stood at $11.7 million in 2020, then spiked by 85.84% to $21.8 million in 2021, then soared by 171.97% to $59.3 million in 2022, then tumbled by 43.12% to $33.7 million in 2023, then slumped by 34.92% to $22.0 million in 2024.